The European Commission authorized Johnson & Johnson's Lazcluze and Rybrevant combination therapy for first-line treatment of specific NSCLC cases, showing significant efficacy compared to Tagrisso. This approval challenges Tagrisso's dominance in the market, with promising sales forecasts for the new combination therapy.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing